Vincent M. Isabella

3.7k citations

31 papers · 2.8k indexed · 4 hit papers · h-index 19

Molecular Medicine top 1%
- Antibiotic Resistance in Bacteria 4
Microbiology top 1%
Endocrinology top 2%
Biotechnology top 1%
Molecular Biology top 5%
- Bacterial biofilms and quorum sensing 4
- Heme Oxygenase-1 and Carbon Monoxide 3
Clinical Biochemistry
- Metabolism and Genetic Disorders 6
Genetics
- Bacterial Genetics and Biotechnology 6
Physiology
- Nitric Oxide and Endothelin Effects 4
Biochemistry
- Amino Acid Enzymes and Metabolism 3
Food Science
- Probiotics and Fermented Foods 3

Co-authors: Kim Lewis Caroline Kurtz Lawrence Mulcahy Mark R. CharbonneauNing LiVirginia L. Clark Ernesto Nakayasu Brian P. Conlon
Cited by: Molecular Medicine Microbiology Endocrinology
Journals: Microbiology (4 papers)Molecular Microbiology (2 papers)Nature Communications (2 papers)
Partner nations: United States Italy

In The Last Decade

Vincent M. Isabella

30 papers receiving 2.7k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2020 Nature Communications
2019 Science Translational Medicine
2018 Nature Biotechnology
2013 Nature

Peers

Countries citing papers authored by Vincent M. Isabella

Since Specialization

Citations

This map shows the geographic impact of Vincent M. Isabella's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent M. Isabella with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent M. Isabella more than expected).

Fields of papers citing papers by Vincent M. Isabella

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincent M. Isabella. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent M. Isabella. The network helps show where Vincent M. Isabella may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Vincent M. Isabella, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Vincent M. Isabella Line = papers co-authored together Vincent M. Isabella links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The live biotherapeutic SYNB1353 decreases plasma methionine via directed degradation in animal models and healthy volunteers Cell Host & Microbe ·Mylène Perreault,Віталій Петрович Стриженок,浩二楠本,Michael J. James,Sean L. Cotton,K. H. Kang,Mark D. Simon,冀北,Nathan W. Schmidt,اعظم مشفق,진선옥,Neal Sondheimer,Thaler Alex,William S. Denney,Vincent M. Isabella,David Lubkowicz,Aoife M. Brennan,David L. Hava	2024	23
2	Redesign of an Escherichia coli Nissle treatment for phenylketonuria using insulated genomic landing pads and genetic circuits to reduce burden Cell Systems ·Alexander J. Triassi,Brandon D. Fields,D. Saracino,Віталій Петрович Стриженок,Yongjin Park,Cheung Yin-Bun,徹秋本,Vincent M. Isabella,Christopher A. Voigt	2023	16
3	An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria Molecular Systems Biology ·David Lubkowicz,A. Rabsztyn,Michael J. James,力也近藤,Kaijuan Wang,K. H. Kang,Ron B. Shmueli,Shaw Dp,Jianrong Gao,Caroline Kurtz,Mylène Perreault,Mark R. Charbonneau,Vincent M. Isabella,David L. Hava	2022	35
4	Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineering Nature Communications ·Sanjay A . Patil,O. Jungling,Olga Dortmann,Per Greisen,James Spoonamore,Munira Momin,N. G. Kljujewa,Mary Joan Castillo,Lindong Weng,Kaijuan Wang,Schwabe,Jay H. Konieczka,Teodelinda Mirabella,賛恵光林,Adam G. Lawrence,Vincent M. Isabella	2021	76
5	Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study Nature Metabolism ·Marja Puurunen,Jerry Vockley,朱晓林,Stephanie Sacharow,John A. Phillips,William S. Denney,Benjamin D. Goodlett,David A. Wagner,Larry Blankstein,Mary Joan Castillo,Mark R. Charbonneau,Vincent M. Isabella,Zhang Peibi,Richard J. Riese,Caroline Kurtz,Aoife M. Brennan	2021	105
6	Development of a Synthetic Biotic, SYNB8802, for the Treatment of Enteric Hyperoxaluria Journal of the American Society of Nephrology ·Kaijuan Wang,David Lubkowicz,本多倫彬,Alan Ping-lin Liu,P Pulickal,Michael J. James,力也近藤,Mark R. Charbonneau,Ron B. Shmueli,J. R. Gao,Vincent M. Isabella,Mylène Perreault	2020	0
7	Developing a new class of engineered live bacterial therapeutics to treat human diseasesbreakdown → Nature Communications ·Mark R. Charbonneau,Vincent M. Isabella,Ning Li,Caroline Kurtz	2020	313
8	An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humansbreakdown → Science Translational Medicine ·Caroline Kurtz,Yves Millet,Marja Puurunen,Mylène Perreault,Mark R. Charbonneau,Vincent M. Isabella,Jonathan W. Kotula,Oliver B Patton,Yossi Dagon,William S. Denney,David A. Wagner,Kip A. West,Herbert Feis,Aoife M. Brennan,Paul Miller	2019	280
9	Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuriabreakdown → Nature Biotechnology ·Vincent M. Isabella,ShrutiKa Khobragade,Mary Joan Castillo,David Lubkowicz,Sarah E. Rowe,Yves Millet,Shaw Dp,Ning Li,Adam Fisher,Kip A. West,Citro Rodolfo,Munira Momin,K. H. Kang,Xi Zhang,Paul Miller,Caroline Kurtz,Dean Falb	2018	403
10	Abstract 2920: Metabolic modulation of the tumor microenvironment using Synthetic Biotic™ Medicines Cancer Research ·Kip A. West,Adam Fisher,坊博,Anna Sokolovska,Ning Li,Ricki Diane Weinberger,Mary Joan Castillo,Vincent M. Isabella,Starsha Kolodziej,Paul Miller,José M. Lora	2018	5
11	Toward the Rational Design of Carbapenem Uptake in Pseudomonas aeruginosa Chemistry & Biology ·Vincent M. Isabella,Arthur J. Campbell,John I. Manchester,Mark Sylvester,Asha S. Nayar,Keith Ferguson,Rubén Tommasi,Alita A. Miller	2015	52
12	Thinking Outside the “Bug”: A Unique Assay To Measure Intracellular Drug Penetration in Gram-Negative Bacteria Analytical Chemistry ·Ying Zhou,Camil Joubran,Ho-Gyu Yoon,Vincent M. Isabella,Asha S. Nayar,Sharon Tentarelli,Alita A. Miller	2015	58
13	Characterization of novel respiratory syncytial virus inhibitors identified by high throughput screen Antiviral Research ·Yujie Wang,Ewan F. Dunn,Robert E. McLaughlin,Kiyotugu SAGAWA,Olga Yuzhakov,Vincent M. Isabella,Pamela Hill,Qin Yu	2014	17
14	Activated ClpP kills persisters and eradicates a chronic biofilm infectionbreakdown → Nature ·Brian P. Conlon,Ernesto Nakayasu,L Fleck,Michael D. LaFleur,Vincent M. Isabella,K. Coleman,Steve N. Leonard,Richard Smith,Joshua Adkins,Kim Lewis	2013	520
15	Pseudomonas aeruginosa Biofilms in Disease Microbial Ecology ·Lawrence Mulcahy,Vincent M. Isabella,Kim Lewis	2013	375
16	Identification of a conserved protein involved in anaerobic unsaturated fatty acid synthesis in Neiserria gonorrhoeae: implications for facultative and obligate anaerobes that lack FabA Molecular Microbiology ·Vincent M. Isabella,Virginia L. Clark	2011	15
17	Deep sequencing-based analysis of the anaerobic stimulon in Neisseria gonorrhoeae BMC Genomics ·Vincent M. Isabella,Virginia L. Clark	2011	69
18	Functional analysis of NsrR, a nitric oxide‐sensing Rrf2 repressor in Neisseria gonorrhoeae Molecular Microbiology ·Vincent M. Isabella,John D. Lapek,Edward M. Kennedy,Virginia L. Clark	2008	52
19	cis- and trans-acting elements involved in regulation of norB (norZ), the gene encoding nitric oxide reductase in Neisseria gonorrhoeae Microbiology ·Vincent M. Isabella,Lori Wright,S.kep. Nurbaiti,照雄門脇,Vitor Germano Piscitelli Alvarenga Lanna,Caroline A. Genco,Virginia L. Clark	2008	37
20	Analysis of the hierarchy of quorum-sensing regulation in Pseudomonas aeruginosa Analytical and Bioanalytical Chemistry ·Victoria Wagner,Et al. R. P.Patange,Vincent M. Isabella,Barbara H. Iglewski	2006	68

About Vincent M. Isabella

Vincent M. Isabella is a scholar working on Clinical Biochemistry, Molecular Medicine, Microbiology, Biochemistry and Biological Psychiatry, having authored 31 papers that have together received 2.8k indexed citations. Recurring topics across this work include Metabolism and Genetic Disorders (6 papers), Bacterial Genetics and Biotechnology (6 papers), Nitric Oxide and Endothelin Effects (4 papers), Antibiotic Resistance in Bacteria (4 papers), Bacterial biofilms and quorum sensing (4 papers), Amino Acid Enzymes and Metabolism (3 papers), Probiotics and Fermented Foods (3 papers) and Heme Oxygenase-1 and Carbon Monoxide (3 papers). The work is most often cited by research in Molecular Medicine (426 citations), Microbiology (315 citations), Endocrinology (246 citations), Biotechnology (362 citations) and Molecular Biology (1.7k citations). Vincent M. Isabella has collaborated with scholars based in United States and Italy. Frequent co-authors include Kim Lewis, Caroline Kurtz, Lawrence Mulcahy, Mark R. Charbonneau, Ning Li, Virginia L. Clark, Ernesto Nakayasu, Brian P. Conlon, L Fleck and K. Coleman. Their work appears in journals such as Microbiology, Molecular Microbiology, Nature Communications, Journal of Bacteriology and Analytical and Bioanalytical Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact